PRAXIS PrOgress PrOSPeCT Traineeship Program
Leading education provider PRAXIS Australia has partnered with Omico to deliver a prestigious, innovative program that will open new cancer treatment paths and clinical trial careers for Australians.
Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) is a ground-breaking initiative that harnesses cutting-edge technology in precision medicine and comprehensive genomic profiling (CGP) to accelerate personalised treatment whilst maximising opportunities in clinical trials. The program is a national first.
PRAXIS Australia has been selected to deliver innovative training and traineeship support that will underpin PrOSPeCT’s activities.
PRAXIS will provide training for 40 clinical trial coordinators and research associates across Australia. Opening pathways in regional, rural, and remote areas, to Aboriginal and Torres Strait Islander Peoples and people of varying cultural and language diversity is an important aim of the program.
The program will have a national reach, and regional, rural and remote applications are encouraged.
Program delivery to be comprised of 2 x 5-month cohorts of 20 trainees for each cohort.
The program will provide entry level and more advanced level traineeship options.
The first intake of Clinical Trial Coordinators will be in September 2023.
The second intake will commence in February 2024.
Who should apply?
Professionals from various clinical trial roles.
Aboriginal and Torres Strait Islander people are encouraged to apply.
Applications are also encouraged from regional, rural and remote participants.
Traineeships are only available to Australian citizens and permanent residents.
Host site opportunities will be offered first to the PrOSPeCT National Clinical Trials Network (NCTN) sites.
For organisations outside NCTN sites, we can advertise their availability to allied Clinical Trial Units.
The commitment is to traineeships, with the aim to help with linkages where relevant in recruitment or placements post training to NCTN members.